STUDY OBJECTIVES: Screening for sleep apnea may be useful in a number of settings, such as preoperative testing, clinical research, and evaluation for referral to a sleep center. The purpose of the study was to validate the ApneaLink device (ResMed Corporation, Poway, Calif) for use as a screening tool for sleep apnea in clinical practice. METHODS: The ApneaLink device is a single-channel screening tool for sleep apnea that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. We compared the AHI from the ApneaLink device to that obtained during simultaneously conducted attended sleep-laboratory polysomnography to assess the sensitivity and specificity of the device in consecutive subjects with type 2 diabetes mellitus referred from a diabetes clinic. We also compared the AHI obtained from the ApneaLink device during a study in the subjects' homes to that obtained during the in-laboratory study. The laboratory study was performed within 2 weeks of the home study. RESULTS: Fifty-nine subjects completed the study. Mean age of subjects was 57 years; mean body mass index was 33 kg/m2. The results demonstrate a high sensitivity and specificity of the at-home ApneaLink AHI compared with the AHI from the simultaneous polysomnographic study at all AHI levels, with the best results at an AHI of > or =15 events per hour (sensitivity 91%, specificity 95%). The AHI comparison from the home and laboratory studies also demonstrates good sensitivity and specificity at AHI levels of > or =15 and > or =20 events per hour (sensitivity 76%, specificity 94%, for both). CONCLUSIONS: Given the prevalence of sleep apnea in the adult population and in specific comorbid conditions, a screening tool may be useful in many diagnostic settings. This study demonstrates that the ApneaLink device provides reliable information, is a simple, easy-to-use device, and is highly sensitive and specific in calculating AHI, when compared with the AHI obtained from full polysomnography.
STUDY OBJECTIVES: Screening for sleep apnea may be useful in a number of settings, such as preoperative testing, clinical research, and evaluation for referral to a sleep center. The purpose of the study was to validate the ApneaLink device (ResMed Corporation, Poway, Calif) for use as a screening tool for sleep apnea in clinical practice. METHODS: The ApneaLink device is a single-channel screening tool for sleep apnea that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. We compared the AHI from the ApneaLink device to that obtained during simultaneously conducted attended sleep-laboratory polysomnography to assess the sensitivity and specificity of the device in consecutive subjects with type 2 diabetes mellitus referred from a diabetes clinic. We also compared the AHI obtained from the ApneaLink device during a study in the subjects' homes to that obtained during the in-laboratory study. The laboratory study was performed within 2 weeks of the home study. RESULTS: Fifty-nine subjects completed the study. Mean age of subjects was 57 years; mean body mass index was 33 kg/m2. The results demonstrate a high sensitivity and specificity of the at-home ApneaLink AHI compared with the AHI from the simultaneous polysomnographic study at all AHI levels, with the best results at an AHI of > or =15 events per hour (sensitivity 91%, specificity 95%). The AHI comparison from the home and laboratory studies also demonstrates good sensitivity and specificity at AHI levels of > or =15 and > or =20 events per hour (sensitivity 76%, specificity 94%, for both). CONCLUSIONS: Given the prevalence of sleep apnea in the adult population and in specific comorbid conditions, a screening tool may be useful in many diagnostic settings. This study demonstrates that the ApneaLink device provides reliable information, is a simple, easy-to-use device, and is highly sensitive and specific in calculating AHI, when compared with the AHI obtained from full polysomnography.
Authors: W Ward Flemons; Michael R Littner; James A Rowley; Peter Gay; W McDowell Anderson; David W Hudgel; R Douglas McEvoy; Daniel I Loube Journal: Chest Date: 2003-10 Impact factor: 9.410
Authors: E Shahar; C W Whitney; S Redline; E T Lee; A B Newman; F J Nieto; G T O'Connor; L L Boland; J E Schwartz; J M Samet Journal: Am J Respir Crit Care Med Date: 2001-01 Impact factor: 21.405
Authors: Naresh M Punjabi; John D Sorkin; Leslie I Katzel; Andrew P Goldberg; Alan R Schwartz; Philip L Smith Journal: Am J Respir Crit Care Med Date: 2002-03-01 Impact factor: 21.405
Authors: Mary S M Ip; Bing Lam; Matthew M T Ng; Wah Kit Lam; Kenneth W T Tsang; Karen S L Lam Journal: Am J Respir Crit Care Med Date: 2002-03-01 Impact factor: 21.405
Authors: Helaine E Resnick; Susan Redline; Eyal Shahar; Adele Gilpin; Anne Newman; Robert Walter; Gordon A Ewy; Barbara V Howard; Naresh M Punjabi Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112
Authors: Kirk Kee; John Dixon; Jonathan Shaw; Elena Vulikh; Markus Schlaich; David M Kaye; Paul Zimmet; Matthew T Naughton Journal: J Clin Sleep Med Date: 2018-12-15 Impact factor: 4.062
Authors: Lydia Makarie Rofail; Keith K H Wong; Gunnar Unger; Guy B Marks; Ronald R Grunstein Journal: J Clin Sleep Med Date: 2010-08-15 Impact factor: 4.062
Authors: Carla R Jungquist; Jaime Mund; Alan T Aquilina; Karen Klingman; John Pender; Heather Ochs-Balcom; Edwin van Wijngaarden; Suzanne S Dickerson Journal: J Clin Sleep Med Date: 2016-03 Impact factor: 4.062
Authors: Devin L Brown; Ronald D Chervin; James Wolfe; Rebecca Hughes; MaryAnn Concannon; Lynda D Lisabeth; Kristen L Gruis Journal: Neurology Date: 2014-02-28 Impact factor: 9.910
Authors: Devin L Brown; Ashkan Mowla; Mollie McDermott; Lewis B Morgenstern; Garnett Hegeman; Melinda A Smith; Nelda M Garcia; Ronald D Chervin; Lynda D Lisabeth Journal: J Stroke Cerebrovasc Dis Date: 2014-12-10 Impact factor: 2.136